A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Table 3 Durable platelet counts response throughout 24-week treatment with hetrombopag

Endpoints with 24 weeks	HETROM-2.5, n = 168	HETROM-5, n = 171	Hetrombopag, n = 339
Proportion of patients who responded at ≥ 75% of their platelet count assessments
n (%; 95% CI)^‡	67 (39.9; 32.4–47.7)	85 (49.7; 42.0–57.4)	152 (44.8; 39.5–50.3)
Maximum continuous duration of response
n^#	138	149	287
Median (range), days	64.0 (8.0–165.0)	64.0 (6.0–168.0)	64.0 (6.0–168.0)
Total duration of response
n^#	138	149	287
Median (range), days	101.0 (8.0–165.0)	104.0 (6.0–168.0)	103.0 (6.0–168.0)

HETROM-2.5, dosage was titrated from an initial dose of once-daily 2.5 mg hetrombopag; HETROM-5, dosage was titrated from an initial dose of once-daily 5 mg hetrombopag
^‡95% CI was calculated using the Clopper–Pearson method
^#Number of patients achieving response to treatment at consecutive scheduled visits

ISSN: 1756-8722